Arrowstreet Capital Limited Partnership Grows Position in Elevance Health, Inc. $ELV

Key Points

• Arrowstreet Capital increased its stake in Elevance by 60.4% in Q3 to 1,511,604 shares—about 0.68% of the company—worth roughly $488.4 million.
• Quarterly results beat on EPS ($3.33 vs. $3.10 expected) while revenue was $49.31 billion (slightly below estimates) and revenue rose 9.6% year-over-year, with management setting FY2026 guidance near a $25.50 EPS level.
• Dividend boosted—Elevance raised its quarterly payout to $1.72 (annualized $6.88), a ~2.4% yield with a payout ratio around 27%.

Arrowstreet Capital Limited Partnership boosted its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 60.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,511,604 shares of the company's stock after acquiring an additional 569,008 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.68% of Elevance Health worth $488,429,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Elevance Health by 0.6% during the third quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company's stock worth $7,431,322,000 after purchasing an additional 141,747 shares in the last quarter. Sanders Capital LLC lifted its holdings in Elevance Health by 24.7% during the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company's stock worth $2,265,773,000 after buying an additional 1,152,440 shares during the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company's stock worth $1,478,857,000 after acquiring an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company's stock valued at $1,292,029,000 after acquiring an additional 798,457 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Elevance Health in the 2nd quarter valued at about $1,148,379,000. Institutional investors and hedge funds own 89.24% of the company's stock.

Elevance Health Price Performance

ELV stock opened at $288.33 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $63.64 billion, a P/E ratio of 11.48, a PEG ratio of 1.60 and a beta of 0.51. The business has a 50 day simple moving average of $339.50 and a 200-day simple moving average of $334.27. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75.

Elevance Health (NYSE:ELV - Get Free Report) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts' consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to analysts' expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company's quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. This is an increase from Elevance Health's previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health's dividend payout ratio is 27.39%.

Analyst Ratings Changes

Several research firms recently weighed in on ELV. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Robert W. Baird boosted their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the stock a "neutral" rating in a research report on Thursday, December 11th. UBS Group set a $400.00 target price on shares of Elevance Health in a report on Thursday, January 29th. Guggenheim dropped their target price on shares of Elevance Health from $414.00 to $396.00 and set a "buy" rating on the stock in a research report on Thursday, January 29th. Finally, Wall Street Zen lowered shares of Elevance Health from a "buy" rating to a "hold" rating in a research note on Sunday, February 8th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $387.40.

Elevance Health Company Profile

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.